Next-Gen CRMs Transform Rare Disease Care
Approximately four to over 4.5 million people in Germany are living with a rare disease. Managing these conditions effectively requires innovative solutions, as traditional engagement models often fall short. Next-generation Customer Relationship Management (CRM) systems, also known as care credit systems, are emerging as a crucial tool for life sciences companies developing rare disease treatments.
Next-gen CRMs can significantly enhance data orchestration, providing real-time visibility into the patient journey. This enables healthcare providers to make faster, more informed decisions. Unlike traditional systems, next-gen CRMs can connect the patient journey by integrating both clinical and social data. This delivers a comprehensive 360-degree view of each patient, allowing for tailored treatment protocols.
The complex nature of rare diseases, with no standard path to care, necessitates intricate coordination across multiple stakeholders and systems. Capgemini can help navigate this complexity by building and executing a therapeutic area-specific CRM strategy for rare diseases. This strategy can enable new care models, such as value-based care and hyper-personalized treatments like cell and gen x therapy.
Next-gen CRMs can also educate stakeholders, delivering targeted educational campaigns and disseminating them on each stakeholder's preferred channel. They can personalize interactions, providing tailored interventions and real-time updates for each stakeholder in the rare disease journey. This is particularly important given the estimated 300 million people worldwide living with one of the 6,000 recognized rare conditions.
Next-gen CRMs offer a powerful solution for managing rare disease journeys, which are often complex and challenging. By enhancing data orchestration, connecting patient journeys, enabling new care models, educating stakeholders, and personalizing interactions, these systems can significantly improve the lives of millions of people living with rare diseases.
